The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases

Imatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic leukemia (F/P(+) CEL), but its optimal dosing, duration, and possibility of discontinuation are still a matter of debate. A retrospective multicenter study was conducted with 44 F/P(+) CEL patients identified...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Medicine (Baltimore)
Glavni autori: Legrand, Fanny, Renneville, Aline, MacIntyre, Elizabeth, Mastrilli, Samuel, Ackermann, Felix, Cayuela, Jean Michel, Rousselot, Philippe, Schmidt-Tanguy, Aline, Fain, Olivier, Michel, Marc, de Jaureguiberry, Jean-Pierre, Hatron, Pierre-Yves, Cony-Makhoul, Pascale, Lefranc, Didier, Sène, Damien, Cottin, Vincent, Hamidou, Mohamed, Lidove, Olivier, Baruchel, André, Dubucquoi, Sylvain, Bletry, Olivier, Preudhomme, Claude, Capron, Monique, Prin, Lionel, Kahn, Jean Emmanuel
Format: Artigo
Jezik:Inglês
Izdano: Wolters Kluwer Health 2013
Teme:
Original Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4553979/
https://ncbi.nlm.nih.gov/pubmed/23982058
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0b013e3182a71eba
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items